Company profile
Imunon, Inc.
NASDAQ: IMNN · Healthcare · Biotechnology
#932 of 1,418 Healthcare companies by revenue41st-percentile growth
EA Score
39DFH 22DQ 50GM 61SS 56
v0.1 · 65/100 weight · provisional
↑ growth stability, listing tenure · ↓ Piotroski F, Altman-Z
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$14.5M
Employees
20
as of 2026-08-23
Market cap
$6.9M
as of 2026-08-23
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$500.0k$500.0k2022
Net income-$14.5M-$14.5M2025
Operating income-$14.7M-$14.7M2025
Total assets$12.3M$12.3M2025
Liabilities$5.2M$5.2M2025
Equity$7.1M$7.1M2025
Revenue trend
FY2015 – FY2022 · USD
FY15
FY15
FY18
FY18
FY19
FY20
FY21
FY22
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Imunon, Inc.’s revenue?
Imunon, Inc. booked $500.0k in FY2022 revenue, growing 0.0% year over year — about the middle of the pack among Healthcare companies we track, at a -2899.0% net margin.
Peers · Healthcare
Medivolve Inc.——DiaMedica Therapeutics Inc.35DZenith Capital Corp.——Bioelectronics Corporation——Pasithea Therapeutics Corp.32DPositron Corporation28DNeighbors
Mercer →Key facts
CEOStacy R. Lindborg
SectorHealthcare
IndustryBiotechnology
HeadquartersLawrenceville, NJ
ExchangeNASDAQ: IMNN
Employees20
IPO date1999-03-01
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.